On this page
Triamcinolone Acetonide
Overview
Active ingredients
Source: NDC DirectoryForms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Corticosteroid Hormone Receptor Agonists [MoA] | MoA | All 215 members |
| Corticosteroid [EPC] | EPC | All 215 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 087385-001 | TRIAMCINOLONE ACETONIDE | OINTMENT | TRIAMCINOLONE ACETONIDE | Prescription | AT | RLD RS | |
| 087385-002 | TRIAMCINOLONE ACETONIDE | OINTMENT | TRIAMCINOLONE ACETONIDE | Prescription | AT | RLD RS | |
| 087385-003 | TRIAMCINOLONE ACETONIDE | OINTMENT | TRIAMCINOLONE ACETONIDE | Prescription | AT | RLD RS |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 15 | Manufacturing (CMC) | Approved | March 26, 1999 | — |
| Supplement | 13 | Labeling | Approved | June 14, 1995 | — |
| Supplement | 12 | Manufacturing (CMC) | Approved | May 13, 1988 | — |
| Supplement | 10 | Manufacturing (CMC) | Approved | September 23, 1986 | — |
| Supplement | 9 | Manufacturing (CMC) | Approved | June 9, 1986 | — |
| Supplement | 3 | Manufacturing (CMC) | Approved | April 28, 1986 | — |
| Supplement | 4 | Manufacturing (CMC) | Approved | July 11, 1984 | — |
| Original application | 1 | Approved | November 5, 1981 | — |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260317). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Triamcinolone Acetonide 0.05% in Absorbase ® (Triamcinolone Acetonide Ointment, USP) is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Apply a thin film of the 0.1% Triamcinolone Acetonide Ointment, as appropriate, to the affected area two to three times daily. Occlusive Dressing Technique Occlusive dressings may be used for the management of psoriasis or other recalcitrant conditions. Apply a thin film of ointment to the lesion, cover with a pliable nonporous film, and seal the edges. If needed, additional moisture may be provided by covering the lesion with a dampened clean cotton cloth before the nonporous film is applied or by briefly wetting the affected area with water immediately prior to applying the medication. The frequency of changing dressings is best determined on an individual basis. It may be convenient to apply Triamcinolone Acetonide Ointment under an occlusive dressing in the evening and to remove the dressing in the morning (i.e., 12-hour occlusion). When utilizing the 12-hour occlusion regimen, additional ointment should be applied, without occlusion, during the day. Reapplication is essential at each dressing change. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
Occlusive Dressing Technique Occlusive dressings may be used for the management of psoriasis or other recalcitrant conditions. Apply a thin film of ointment to the lesion, cover with a pliable nonporous film, and seal the edges. If needed, additional moisture may be provided by covering the lesion with a dampened clean cotton cloth before the nonporous film is applied or by briefly wetting the affected area with water immediately prior to applying the medication. The frequency of changing dressings is best determined on an individual basis. It may be convenient to apply Triamcinolone Acetonide Ointment under an occlusive dressing in the evening and to remove the dressing in the morning (i.e., 12-hour occlusion). When utilizing the 12-hour occlusion regimen, additional ointment should be applied, without occlusion, during the day. Reapplication is essential at each dressing change. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Triamcinolone Acetonide 0.05% in Absorbase ® (Triamcinolone Acetonide Ointment, USP) is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria. To report SUSPECTED ADVERSE REACTIONS, contact Cosette Pharmaceuticals, Inc. at 1-800-922-1038 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
Description
openFDA Drug LabelingTriamcinolone Acetonide Cream USP contains Triamcinolone Acetonide [Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis- (oxy)]-, (11β,16α)-], with the empirical formula C24H31FO6 and molecular weight 434.50. CAS 76-25-5. [chemstructure] Triamcinolone Acetonide Cream USP, 0.025% contains: 0.25 mg of Triamcinolone Acetonide per gram in a base containing Emulsifying Wax, Cetyl Alcohol, Isopropyl Palmitate, Sorbitol Solution, Glycerin, Lactic Acid, Benzyl Alcohol and Purified Water. Triamcinolone Acetonide Cream USP, 0.1% contains: 1 mg of Triamcinolone Acetonide per gram in a base containing Emulsifying Wax, Cetyl Alcohol, Isopropyl Palmitate, Sorbitol Solution, Glycerin, Lactic Acid, Benzyl Alcohol and Purified Water. Triamcinolone Acetonide Cream USP, 0.5% contains: 5 mg of Triamcinolone Acetonide per gram in a base containing Emulsifying Wax, Cetyl Alcohol, Isopropyl Palmitate, Sorbitol Solution, Glycerin, Lactic Acid, Benzyl Alcohol and Purified Water.
Overdosage
openFDA Drug LabelingOVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS, General ).
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Triamcinolone Acetonide Ointment USP, 0.025% is available as follows: 15 gram tubes NDC 33342-331-15 80 gram tubes NDC 33342-331-80 454 g jar NDC 33342-331-54 Triamcinolone Acetonide Ointment USP, 0.1% is available as follows: 15 gram tubes NDC 33342-333-15 80 gram tubes NDC 33342-333-80 454 g jar NDC 33342-333-54 Triamcinolone Acetonide Ointment USP, 0.5% is available as follows: 15 gram tubes NDC 33342-332-15 Storage Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Manufactured for: Macleods Pharma USA, Inc. Princeton, NJ 08540 Manufacturer: Macleods Pharmaceuticals Limited At Oxalis Labs Baddi, Himachal Pradesh, INDIA To report SUSPECTED ADVERSE REACTIONS, contact Macleods Pharma USA, Inc.at 1-888-943-3210 or 1-855-926- 3384 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Revised: July 2023
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: TRIAMCINOLONE ACETONIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Recalls
Source: FDA Enforcement| Classification | Reported | Firm | Reason | Status |
|---|---|---|---|---|
| Class II | June 2, 2021 | Cardinal Health Inc. | CGMP Deviations: Intermittent exposure to temperature excursion during storage. | Terminated |
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 50090-2244-0 | 50090-2244 | A-S Medication Solutions | 1 TUBE in 1 CARTON (50090-2244-0) / 80 g in 1 TUBE | December 2, 2015 |
| 50090-3508-0 | 50090-3508 | A-S Medication Solutions | 1 TUBE in 1 CARTON (50090-3508-0) / 80 g in 1 TUBE | July 19, 2018 |
| 50090-3802-0 | 50090-3802 | A-S Medication Solutions | 1 TUBE in 1 CARTON (50090-3802-0) / 15 g in 1 TUBE | November 9, 2018 |
| 50090-4761-0 | 50090-4761 | A-S Medication Solutions | 1 TUBE in 1 CARTON (50090-4761-0) / 15 g in 1 TUBE | November 27, 2019 |
| 50090-5980-0 | 50090-5980 | A-S Medication Solutions | 1 TUBE in 1 CARTON (50090-5980-0) / 15 g in 1 TUBE | May 18, 2022 |
| 50090-6211-0 | 50090-6211 | A-S Medication Solutions | 1 TUBE in 1 CARTON (50090-6211-0) / 15 g in 1 TUBE | November 7, 2022 |
| 50090-6978-0 | 50090-6978 | A-S Medication Solutions | 1 TUBE in 1 CARTON (50090-6978-0) / 15 g in 1 TUBE | December 26, 2023 |
| 50090-7679-0 | 50090-7679 | A-S Medication Solutions | 1 TUBE in 1 CARTON (50090-7679-0) / 15 g in 1 TUBE | October 8, 2025 |
| 76420-360-80 | 76420-360 | Asclemed USA, Inc. | 80 g in 1 TUBE (76420-360-80) | May 23, 2025 |
| 76420-361-00 | 76420-361 | Asclemed USA, Inc. | 454 g in 1 JAR (76420-361-00) | May 23, 2025 |
| 76420-361-15 | 76420-361 | Asclemed USA, Inc. | 15 g in 1 TUBE (76420-361-15) | May 23, 2025 |
| 76420-361-80 | 76420-361 | Asclemed USA, Inc. | 80 g in 1 TUBE (76420-361-80) | May 23, 2025 |
| 63629-8708-1 | 63629-8708 | Bryant Ranch Prepack | 430 g in 1 JAR (63629-8708-1) | February 9, 2022 |
| 63629-8841-1 | 63629-8841 | Bryant Ranch Prepack | 80 g in 1 TUBE (63629-8841-1) | September 10, 2021 |
| 72162-1429-2 | 72162-1429 | Bryant Ranch Prepack | 430 g in 1 JAR (72162-1429-2) | June 18, 2024 |
| 72162-2335-2 | 72162-2335 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-2335-2) / 15 g in 1 TUBE | June 18, 2024 |
| 72162-2335-4 | 72162-2335 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-2335-4) / 80 g in 1 TUBE | June 18, 2024 |
| 72162-2336-2 | 72162-2336 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-2336-2) / 15 g in 1 TUBE | June 18, 2024 |
| 72162-2336-4 | 72162-2336 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-2336-4) / 80 g in 1 TUBE | June 18, 2024 |
| 46287-010-11 | 46287-010 | CMP Pharma, Inc. | 110 g in 1 JAR (46287-010-11) | August 23, 2021 |
| 24470-922-15 | 24470-922 | Cintex Services, LLC | 430 g in 1 JAR (24470-922-15) | November 10, 2020 |
| 0713-0228-15 | 0713-0228 | Cosette Pharmaceuticals, Inc. | 1 TUBE in 1 CARTON (0713-0228-15) / 15 g in 1 TUBE | September 10, 2015 |
| 0713-0228-31 | 0713-0228 | Cosette Pharmaceuticals, Inc. | 1 TUBE in 1 CARTON (0713-0228-31) / 30 g in 1 TUBE | December 6, 2024 |
| 0713-0228-80 | 0713-0228 | Cosette Pharmaceuticals, Inc. | 1 TUBE in 1 CARTON (0713-0228-80) / 80 g in 1 TUBE | September 10, 2015 |
| 0713-0229-15 | 0713-0229 | Cosette Pharmaceuticals, Inc. | 1 TUBE in 1 CARTON (0713-0229-15) / 15 g in 1 TUBE | September 10, 2015 |
| 0713-0229-80 | 0713-0229 | Cosette Pharmaceuticals, Inc. | 1 TUBE in 1 CARTON (0713-0229-80) / 80 g in 1 TUBE | September 10, 2015 |
| 61919-619-15 | 61919-619 | DIRECTRX | 15 g in 1 TUBE (61919-619-15) | February 4, 2021 |
| 0168-0005-80 | 0168-0005 | E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC | 80 g in 1 TUBE (0168-0005-80) | February 14, 1978 |
| 0168-0006-15 | 0168-0006 | E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC | 15 g in 1 TUBE (0168-0006-15) | February 14, 1978 |
| 0168-0006-16 | 0168-0006 | E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC | 454 g in 1 JAR (0168-0006-16) | February 14, 1978 |
| 0168-0006-80 | 0168-0006 | E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC | 80 g in 1 TUBE (0168-0006-80) | February 14, 1978 |
| 21922-024-11 | 21922-024 | Encube Ethicals, Inc. | 430 g in 1 JAR (21922-024-11) | December 2, 2019 |
| 21922-063-04 | 21922-063 | Encube Ethicals, Inc. | 1 TUBE in 1 CARTON (21922-063-04) / 15 g in 1 TUBE | August 1, 2023 |
| 21922-063-05 | 21922-063 | Encube Ethicals, Inc. | 1 TUBE in 1 CARTON (21922-063-05) / 30 g in 1 TUBE | March 18, 2025 |
| 21922-063-15 | 21922-063 | Encube Ethicals, Inc. | 1 TUBE in 1 CARTON (21922-063-15) / 80 g in 1 TUBE | August 1, 2023 |
| 21922-063-30 | 21922-063 | Encube Ethicals, Inc. | 454 g in 1 JAR (21922-063-30) | August 1, 2023 |
| 68462-797-17 | 68462-797 | Glenmark Pharmaceuticals Inc., USA | 1 TUBE in 1 CARTON (68462-797-17) / 15 g in 1 TUBE | August 22, 2017 |
| 68462-797-49 | 68462-797 | Glenmark Pharmaceuticals Inc., USA | 1 TUBE in 1 CARTON (68462-797-49) / 80 g in 1 TUBE | August 22, 2017 |
| 68462-797-59 | 68462-797 | Glenmark Pharmaceuticals Inc., USA | 454 g in 1 JAR (68462-797-59) | August 22, 2017 |
| 68462-798-17 | 68462-798 | Glenmark Pharmaceuticals Inc., USA | 1 TUBE in 1 CARTON (68462-798-17) / 15 g in 1 TUBE | July 22, 2016 |
| 33342-331-15 | 33342-331 | Macleods Pharmaceuticals Limited | 1 TUBE in 1 CARTON (33342-331-15) / 15 g in 1 TUBE | November 23, 2018 |
| 33342-331-54 | 33342-331 | Macleods Pharmaceuticals Limited | 454 g in 1 JAR (33342-331-54) | November 23, 2018 |
| 33342-331-80 | 33342-331 | Macleods Pharmaceuticals Limited | 1 TUBE in 1 CARTON (33342-331-80) / 80 g in 1 TUBE | November 23, 2018 |
| 33342-332-15 | 33342-332 | Macleods Pharmaceuticals Limited | 1 TUBE in 1 CARTON (33342-332-15) / 15 g in 1 TUBE | November 23, 2018 |
| 33342-333-15 | 33342-333 | Macleods Pharmaceuticals Limited | 1 TUBE in 1 CARTON (33342-333-15) / 15 g in 1 TUBE | November 23, 2018 |
| 33342-333-54 | 33342-333 | Macleods Pharmaceuticals Limited | 454 g in 1 JAR (33342-333-54) | November 23, 2018 |
| 33342-333-80 | 33342-333 | Macleods Pharmaceuticals Limited | 1 TUBE in 1 CARTON (33342-333-80) / 80 g in 1 TUBE | November 23, 2018 |
| 33342-334-13 | 33342-334 | Macleods Pharmaceuticals Limited | 430 g in 1 JAR (33342-334-13) | August 18, 2023 |
| 16714-267-01 | 16714-267 | NorthStar RxLLC | 1 TUBE in 1 CARTON (16714-267-01) / 15 g in 1 TUBE | April 21, 2022 |
| 16714-267-02 | 16714-267 | NorthStar RxLLC | 1 TUBE in 1 CARTON (16714-267-02) / 80 g in 1 TUBE | April 21, 2022 |
| 16714-267-03 | 16714-267 | NorthStar RxLLC | 454 g in 1 JAR (16714-267-03) | April 21, 2022 |
| 16714-268-01 | 16714-268 | NorthStar RxLLC | 1 TUBE in 1 CARTON (16714-268-01) / 15 g in 1 TUBE | April 21, 2022 |
| 16714-276-01 | 16714-276 | NorthStar RxLLC | 1 TUBE in 1 CARTON (16714-276-01) / 15 g in 1 TUBE | April 2, 2025 |
| 16714-276-02 | 16714-276 | NorthStar RxLLC | 1 TUBE in 1 CARTON (16714-276-02) / 80 g in 1 TUBE | April 2, 2025 |
| 16714-276-03 | 16714-276 | NorthStar RxLLC | 454 g in 1 JAR (16714-276-03) | April 2, 2025 |
| 72603-319-01 | 72603-319 | Northstar Rx LLC | 430 g in 1 JAR (72603-319-01) | November 1, 2024 |
| 68071-1872-8 | 68071-1872 | NuCare Pharmaceuticals,Inc. | 80 g in 1 BOX (68071-1872-8) | May 4, 2020 |
| 68071-2362-5 | 68071-2362 | NuCare Pharmaceuticals,Inc. | 1 TUBE in 1 CARTON (68071-2362-5) / 15 g in 1 TUBE | March 11, 2021 |
| 68071-4286-5 | 68071-4286 | NuCare Pharmaceuticals,Inc. | 15 g in 1 BOX (68071-4286-5) | February 15, 2018 |
| 45802-049-35 | 45802-049 | Padagis Israel Pharmaceuticals Ltd | 1 TUBE in 1 CARTON (45802-049-35) / 15 g in 1 TUBE | November 10, 2006 |
| 45802-054-05 | 45802-054 | Padagis Israel Pharmaceuticals Ltd | 454 g in 1 JAR (45802-054-05) | July 5, 2007 |
| 45802-054-35 | 45802-054 | Padagis Israel Pharmaceuticals Ltd | 1 TUBE in 1 CARTON (45802-054-35) / 15 g in 1 TUBE | May 12, 2006 |
| 45802-054-36 | 45802-054 | Padagis Israel Pharmaceuticals Ltd | 1 TUBE in 1 CARTON (45802-054-36) / 80 g in 1 TUBE | September 5, 2007 |
| 45802-055-05 | 45802-055 | Padagis Israel Pharmaceuticals Ltd | 454 g in 1 JAR (45802-055-05) | August 4, 2006 |
| 45802-055-35 | 45802-055 | Padagis Israel Pharmaceuticals Ltd | 1 TUBE in 1 CARTON (45802-055-35) / 15 g in 1 TUBE | March 13, 2007 |
| 45802-055-36 | 45802-055 | Padagis Israel Pharmaceuticals Ltd | 1 TUBE in 1 CARTON (45802-055-36) / 80 g in 1 TUBE | October 2, 2006 |
| 45802-817-01 | 45802-817 | Padagis Israel Pharmaceuticals Ltd | 430 g in 1 JAR (45802-817-01) | March 1, 2021 |
| 63187-495-15 | 63187-495 | Proficient Rx LP | 1 TUBE in 1 CARTON (63187-495-15) / 15 g in 1 TUBE | February 2, 2015 |
| 71205-033-15 | 71205-033 | Proficient Rx LP | 1 TUBE in 1 CARTON (71205-033-15) / 15 g in 1 TUBE | May 1, 2018 |
| 71205-038-15 | 71205-038 | Proficient Rx LP | 1 TUBE in 1 CARTON (71205-038-15) / 15 g in 1 TUBE | May 1, 2018 |
| 71205-108-15 | 71205-108 | Proficient Rx LP | 1 TUBE in 1 CARTON (71205-108-15) / 15 g in 1 TUBE | September 4, 2018 |
| 71205-108-80 | 71205-108 | Proficient Rx LP | 1 TUBE in 1 CARTON (71205-108-80) / 80 g in 1 TUBE | September 4, 2018 |
| 82804-019-15 | 82804-019 | Proficient Rx LP | 1 TUBE in 1 CARTON (82804-019-15) / 15 g in 1 TUBE | October 9, 2023 |
| 82804-079-30 | 82804-079 | Proficient Rx LP | 1 TUBE in 1 CARTON (82804-079-30) / 30 g in 1 TUBE | March 13, 2024 |
| 70518-3689-0 | 70518-3689 | REMEDYREPACK INC. | 1 TUBE in 1 CARTON (70518-3689-0) / 80 g in 1 TUBE | March 22, 2023 |
| 70518-4205-0 | 70518-4205 | REMEDYREPACK INC. | 1 TUBE in 1 CARTON (70518-4205-0) / 15 g in 1 TUBE | October 7, 2024 |
| 70518-4546-0 | 70518-4546 | REMEDYREPACK INC. | 1 TUBE in 1 CARTON (70518-4546-0) / 15 g in 1 TUBE | January 15, 2026 |
| 67296-2327-1 | 67296-2327 | Redpharm Drug | 1 TUBE in 1 CARTON (67296-2327-1) / 15 g in 1 TUBE | April 2, 2025 |
| 67296-1927-1 | 67296-1927 | RedpharmDrug | 1 TUBE in 1 CARTON (67296-1927-1) / 15 g in 1 TUBE | September 10, 2015 |
| 64380-901-90 | 64380-901 | Strides Pharma Science Limited | 430 g in 1 JAR (64380-901-90) | June 5, 2020 |
| 51672-1284-1 | 51672-1284 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (51672-1284-1) / 15 g in 1 TUBE | September 30, 1994 |
| 51672-1284-2 | 51672-1284 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (51672-1284-2) / 30 g in 1 TUBE | October 26, 2016 |
| 51672-1284-8 | 51672-1284 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (51672-1284-8) / 80 g in 1 TUBE | September 30, 1994 |
| 50090-2244 | 50090-2244 | A-S Medication Solutions | — | September 30, 1994 |
| 50090-3508 | 50090-3508 | A-S Medication Solutions | — | August 4, 2006 |
| 50090-3802 | 50090-3802 | A-S Medication Solutions | — | September 10, 2015 |
| 50090-4761 | 50090-4761 | A-S Medication Solutions | — | August 4, 2006 |
| 50090-5980 | 50090-5980 | A-S Medication Solutions | — | November 10, 2006 |
| 50090-6211 | 50090-6211 | A-S Medication Solutions | — | July 22, 2016 |
| 50090-6978 | 50090-6978 | A-S Medication Solutions | — | November 23, 2018 |
| 50090-7679 | 50090-7679 | A-S Medication Solutions | — | August 1, 2023 |
| 76420-360 | 76420-360 | Asclemed USA, Inc. | — | February 14, 1978 |
| 76420-361 | 76420-361 | Asclemed USA, Inc. | — | February 14, 1978 |
| 63629-8708 | 63629-8708 | Bryant Ranch Prepack | — | March 1, 2021 |
| 63629-8841 | 63629-8841 | Bryant Ranch Prepack | — | February 14, 1978 |
| 72162-1429 | 72162-1429 | Bryant Ranch Prepack | — | March 1, 2021 |
| 72162-2335 | 72162-2335 | Bryant Ranch Prepack | — | May 12, 2006 |
| 72162-2336 | 72162-2336 | Bryant Ranch Prepack | — | August 4, 2006 |
| 46287-010 | 46287-010 | CMP Pharma, Inc. | — | August 23, 2021 |
| 24470-922 | 24470-922 | Cintex Services, LLC | — | November 10, 2020 |
| 0713-0228 | 0713-0228 | Cosette Pharmaceuticals, Inc. | — | September 10, 2015 |
| 0713-0229 | 0713-0229 | Cosette Pharmaceuticals, Inc. | — | September 10, 2015 |
| 61919-619 | 61919-619 | DIRECTRX | — | February 4, 2021 |
| 0168-0005 | 0168-0005 | E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC | — | February 14, 1978 |
| 0168-0006 | 0168-0006 | E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC | — | February 14, 1978 |
| 21922-024 | 21922-024 | Encube Ethicals, Inc. | — | December 2, 2019 |
| 21922-063 | 21922-063 | Encube Ethicals, Inc. | — | August 1, 2023 |
| 68462-797 | 68462-797 | Glenmark Pharmaceuticals Inc., USA | — | August 22, 2017 |
| 68462-798 | 68462-798 | Glenmark Pharmaceuticals Inc., USA | — | July 22, 2016 |
| 33342-331 | 33342-331 | Macleods Pharmaceuticals Limited | — | November 23, 2018 |
| 33342-332 | 33342-332 | Macleods Pharmaceuticals Limited | — | November 23, 2018 |
| 33342-333 | 33342-333 | Macleods Pharmaceuticals Limited | — | November 23, 2018 |
| 33342-334 | 33342-334 | Macleods Pharmaceuticals Limited | — | August 18, 2023 |
| 16714-267 | 16714-267 | NorthStar RxLLC | — | April 21, 2022 |
| 16714-268 | 16714-268 | NorthStar RxLLC | — | April 21, 2022 |
| 16714-276 | 16714-276 | NorthStar RxLLC | — | April 2, 2025 |
| 72603-319 | 72603-319 | Northstar Rx LLC | — | November 1, 2024 |
| 68071-1872 | 68071-1872 | NuCare Pharmaceuticals,Inc. | — | August 4, 2006 |
| 68071-2362 | 68071-2362 | NuCare Pharmaceuticals,Inc. | — | November 23, 2018 |
| 68071-4286 | 68071-4286 | NuCare Pharmaceuticals,Inc. | — | August 4, 2006 |
| 45802-049 | 45802-049 | Padagis Israel Pharmaceuticals Ltd | — | November 10, 2006 |
| 45802-054 | 45802-054 | Padagis Israel Pharmaceuticals Ltd | — | May 12, 2006 |
| 45802-055 | 45802-055 | Padagis Israel Pharmaceuticals Ltd | — | August 4, 2006 |
| 45802-817 | 45802-817 | Padagis Israel Pharmaceuticals Ltd | — | March 1, 2021 |
| 63187-495 | 63187-495 | Proficient Rx LP | — | November 10, 2006 |
| 71205-033 | 71205-033 | Proficient Rx LP | — | March 3, 2017 |
| 71205-038 | 71205-038 | Proficient Rx LP | — | March 3, 2017 |
| 71205-108 | 71205-108 | Proficient Rx LP | — | August 4, 2006 |
| 82804-019 | 82804-019 | Proficient Rx LP | — | November 23, 2018 |
| 82804-079 | 82804-079 | Proficient Rx LP | — | September 30, 1994 |
| 70518-3689 | 70518-3689 | REMEDYREPACK INC. | — | March 22, 2023 |
| 70518-4205 | 70518-4205 | REMEDYREPACK INC. | — | October 7, 2024 |
| 70518-4546 | 70518-4546 | REMEDYREPACK INC. | — | January 15, 2026 |
| 67296-2327 | 67296-2327 | Redpharm Drug | — | April 2, 2025 |
| 67296-1927 | 67296-1927 | RedpharmDrug | — | September 10, 2015 |
| 64380-901 | 64380-901 | Strides Pharma Science Limited | — | June 5, 2020 |
| 51672-1284 | 51672-1284 | Sun Pharmaceutical Industries, Inc. | — | September 30, 1994 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
| Enforcement | FDA | Recall records |
Generated September 25, 2026 · 13 sections on this page.